This website requires Javascript for some parts to function propertly. Your experience may vary.

Hengeler Mueller advises PAI Partners and Apleona on its merger with Gegenbauer Group | Hengeler Mueller News

Hengeler Mueller advises PAI Partners and Apleona on its merger with Gegenbauer Group

Apleona, a European market leader in integrated facility management, based near Frankfurt am Main, has announced a merger agreement with Gegenbauer Group, one of the leading facility management providers in Germany. As part of the transaction, the former shareholders of the Gegenbauer Group will become shareholders in Apleona, while European private equity firm PAI Partners will remain Apleona’s majority shareholder.

Following the merger, Apleona will become an integrated real estate services firm with more than 40,000 employees across Europe, generating annual sales of around EUR 3.5 billion. The transaction is subject to approval from antitrust authorities and is expected to be completed by the summer of 2023. Once antitrust authorities have approved the merger, all assets will be transferred to the Apleona Group. All business will be continued under the Apleona brand following the merger.

The Hengeler Mueller team was led by partners Daniel Möritz and Emanuel Strehle (both M&A/Private Equity, Munich) and included partners Alf-Henrik Bischke (Antitrust, Dusseldorf), Gunther Wagner (Tax, Munich), Hendrik Bockenheimer (Employment, Frankfurt) and Jan Bonhage (Public Law, Berlin), counsels Anja Balitzki (Antitrust), Matthias Rothkopf (IP, both Dusseldorf) and Erasmus Hoffmann (Public Law, Berlin) as well as associates Ingo Berner (Berlin), Christoph Roth, Maximilian Mayer (both Munich), Tobias Schneiders (Dusseldorf, all M&A), Sebastian Adam (Tax, Frankfurt), Christian Dankerl (Antitrust, Dusseldorf), Kevin Marschhäuser (Public Law, Berlin), Selina Rohr, Musa Müjdeci (both Employment) and Patrick M. Schmidt (IP, all Frankfurt).

Latest Articles

New AML Guidance from BaFin and FIU

BRUSSELS À JOUR - More Pills to Swallow – Antitrust Scrutiny in the Pharmaceutical Sector remains High

Federal Court Decision on Scraping Increases GDPR-related Litigation Risks

Recent Mergers & Acquisitions Work